

Losartan (Cozaar)

OVERVIEW

Indication

Hypertension, nephropathy in patients with type 2 diabetes, reduction in the risk of stroke in patients with hypertension and left ventricular hypertrophy

Launch date

April 2010

Therapeutic class

Antihypertensive agent, Angiotensin II Receptor blocker (ARB)

Available strengths formulation

Oral tablet: 25 mg, 50 mg, 100 mg

Alternative therapeutic options

Generics: benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, quinapril, ramipril, trandolapril

Preferred brands: Benicar, Diovan

Non-preferred brands*: Atacand, Avapro, Micardis, Teveten

* Applicable to three-tier benefit designs only

Anticipated impact

Losartan is the first ARB available in the generic formulation and will serve as a therapeutic alternative for members taking brand name ARBs.

FutureScripts® response

Losartan will be immediately available at the generic formulary cost-sharing tier.

FutureScripts is in the process of reviewing the oral antihypertensive agents clinical policy to determine the best course of action.

References

- Facts and Comparisons website [ARBs]. Available at www.factsandcomparisons.com. Viewed September 24, 2009.
- Micromedex website [Cozaar]. Available at www.micromedex.com. Viewed September 24, 2009.

Note: The information in this document is provided for reference only and is partly based on information derived from third parties. The information is current as of the time of this publication's distribution and may be subject to change.

FutureScripts

For more information, contact your client manager.

